Jinling Pharmaceutical Company Limited

SZSE:000919 株式レポート

時価総額:CN¥4.1b

Jinling Pharmaceutical 過去の業績

過去 基準チェック /16

Jinling Pharmaceutical has been growing earnings at an average annual rate of 0.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 2.9% per year. Jinling Pharmaceutical's return on equity is 1.6%, and it has net margins of 2.5%.

主要情報

0.5%

収益成長率

-0.02%

EPS成長率

Pharmaceuticals 業界の成長10.9%
収益成長率2.9%
株主資本利益率1.6%
ネット・マージン2.5%
前回の決算情報30 Sep 2024

最近の業績更新

Earnings Troubles May Signal Larger Issues for Jinling Pharmaceutical (SZSE:000919) Shareholders

May 06
Earnings Troubles May Signal Larger Issues for Jinling Pharmaceutical (SZSE:000919) Shareholders

Recent updates

Earnings Troubles May Signal Larger Issues for Jinling Pharmaceutical (SZSE:000919) Shareholders

May 06
Earnings Troubles May Signal Larger Issues for Jinling Pharmaceutical (SZSE:000919) Shareholders

収支内訳

Jinling Pharmaceutical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

SZSE:000919 収益、費用、利益 ( )CNY Millions
日付収益収益G+A経費研究開発費
30 Sep 242,90273425101
30 Jun 242,8557442489
31 Mar 242,82410042986
31 Dec 232,78610042479
30 Sep 232,72111041271
30 Jun 232,76012440182
31 Mar 232,68611038679
01 Jan 232,67110538574
30 Sep 222,75211637963
30 Jun 222,73910438354
31 Mar 222,80012538560
01 Jan 222,80912138357
30 Sep 212,7968539354
30 Jun 212,78311738047
31 Mar 212,69212835141
31 Dec 202,5046532844
30 Sep 202,413-1330645
30 Jun 202,389-5830347
31 Mar 202,435-9332445
31 Dec 192,53514534944
30 Sep 192,53235934334
30 Jun 192,62338037530
31 Mar 192,72140539229
01 Jan 192,89924242734
30 Sep 183,03211352149
30 Jun 183,04612648960
31 Mar 183,15214149653
31 Dec 173,19213747939
30 Sep 173,39117041018
30 Jun 173,4811714310
31 Mar 173,5401754390
31 Dec 163,5791804440
30 Sep 163,5262004590
30 Jun 163,4622024430
31 Mar 163,3791994590
31 Dec 153,2212084460
30 Sep 153,0611974300
30 Jun 152,9582044370
31 Mar 152,8492144260
31 Dec 142,7721974070
30 Sep 142,7811964290
30 Jun 142,7081834100
31 Mar 142,6391663820
31 Dec 132,6061563780

質の高い収益: 000919 has a large one-off gain of CN¥31.5M impacting its last 12 months of financial results to 30th September, 2024.

利益率の向上: 000919's current net profit margins (2.5%) are lower than last year (4%).


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: 000919's earnings have grown by 0.5% per year over the past 5 years.

成長の加速: 000919's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

収益対業界: 000919 had negative earnings growth (-33.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).


株主資本利益率

高いROE: 000919's Return on Equity (1.6%) is considered low.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘